Reaktionsgleichung
[F:1][C:2]1([F:21])[CH2:5][N:4]([C:6]2[C:7]([O:15][CH2:16][C:17]([F:20])([F:19])[F:18])=[CH:8][C:9]([C:12]([OH:14])=O)=[N:10][CH:11]=2)[CH2:3]1.[NH2:22][C:23]([CH:29]1[CH2:31][CH2:30]1)([CH3:28])[CH2:24][C:25]([NH2:27])=[O:26]>>[NH2:27][C:25](=[O:26])[CH2:24][C:23]([NH:22][C:12]([C:9]1[CH:8]=[C:7]([O:15][CH2:16][C:17]([F:20])([F:19])[F:18])[C:6]([N:4]2[CH2:5][C:2]([F:21])([F:1])[CH2:3]2)=[CH:11][N:10]=1)=[O:14])([CH:29]1[CH2:31][CH2:30]1)[CH3:28]Komponenten
3
Versuchsvorschrift
The title compound was synthesized in analogy to Example 112e, using 5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridine-2-carboxylic acid (example 223b) and 3-amino-3-cyclopropyl-butanamide (example 270c) as starting materials and isolated (70 mg, 63%) as a racemate; MS (ESI, m/z): 437.3 (M+H+).
Aufarbeitung
- customisolated (70 mg, 63%) as a racemate
Quellen und Nachweise
- ORD-Eintrag
- ord-1d3439573eb940859541f572a3e3fec2
- Quelldatensatz
- uspto-grants-2016_08
- Patentnummer
- US09409866B2
Verknüpfte Notizen
Wird geladen…